Deciphering permissivity of human tumor ecosystems to oncolytic viruses

IF 6.9 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Oncogene Pub Date : 2025-03-27 DOI:10.1038/s41388-025-03357-5

Benjamin Schoeps, Ulrich M. Lauer, Knut Elbers

引用次数: 0

Abstract

Effective cancer therapy involves initiation of a tumor-specific immune response. Consequently, the interest in oncolytic viruses (OV) capable of triggering immunogenic cell death has sparked in recent years. However, the common use of pre-clinical models that fail to mirror patient tumor ecosystems (TES) hinders clinical translation. Here, we provide a condensed view on the intricate interplay between several aspects of TES and OV action and discuss these considerations in the view of recently developed pre-clinical human model systems. Given the urgent demand for innovative cancer treatments, the purpose of this review is to highlight the so-far overlooked complex impact of the tumor microenvironment (TME) on OV permissivity, with the intent to provide a foundation for future, more effective pre-clinical studies.

Abstract Image

查看原文本刊更多论文

破译人类肿瘤生态系统对溶瘤病毒的容忍度。

有效的癌症治疗涉及肿瘤特异性免疫反应的启动。因此，近年来对能够引发免疫原性细胞死亡的溶瘤病毒（OV）产生了兴趣。然而，不能反映患者肿瘤生态系统（TES）的临床前模型的普遍使用阻碍了临床转化。在这里，我们对TES和OV作用的几个方面之间复杂的相互作用提供了一个简明的观点，并从最近开发的临床前人体模型系统的角度讨论了这些考虑。鉴于对创新癌症治疗的迫切需求，本综述的目的是强调迄今为止被忽视的肿瘤微环境（TME）对OV许可性的复杂影响，旨在为未来更有效的临床前研究提供基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncogene 医学-生化与分子生物学

CiteScore

15.30

自引率

1.20%

发文量

404

审稿时长

1 months

期刊介绍： Oncogene is dedicated to advancing our understanding of cancer processes through the publication of exceptional research. The journal seeks to disseminate work that challenges conventional theories and contributes to establishing new paradigms in the etio-pathogenesis, diagnosis, treatment, or prevention of cancers. Emphasis is placed on research shedding light on processes driving metastatic spread and providing crucial insights into cancer biology beyond existing knowledge. Areas covered include the cellular and molecular biology of cancer, resistance to cancer therapies, and the development of improved approaches to enhance survival. Oncogene spans the spectrum of cancer biology, from fundamental and theoretical work to translational, applied, and clinical research, including early and late Phase clinical trials, particularly those with biologic and translational endpoints.